BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1030 related articles for article (PubMed ID: 25563469)

  • 1. Old markers, new approach to assessment of risk in heart failure.
    Kodziszewska K; Leszek P; Korewicki J; Piotrowski W
    Kardiol Pol; 2015; 73(6):387-95. PubMed ID: 25563469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe chronic heart failure in patients considered for heart transplantation in Poland.
    Korewicki J; Leszek P; Zieliński T; Rywik T; Piotrowski W; Kurjata P; Kozar-Kamińska K; Kodziszewska K;
    Cardiol J; 2012; 19(1):36-44. PubMed ID: 22298166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ivabradine therapy on heart failure biomarkers.
    Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
    Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prognostic Value of Serum Levels of Heart-Type Fatty Acid Binding Protein and High Sensitivity C-Reactive Protein in Patients With Increased Levels of Amino-Terminal Pro-B Type Natriuretic Peptide.
    Jeong JH; Seo YH; Ahn JY; Kim KH; Seo JY; Kim MJ; Lee HT; Park PW
    Ann Lab Med; 2016 Sep; 36(5):420-6. PubMed ID: 27374706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
    Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
    Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease.
    Bibbins-Domingo K; Gupta R; Na B; Wu AH; Schiller NB; Whooley MA
    JAMA; 2007 Jan; 297(2):169-76. PubMed ID: 17213400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aminoterminal pro type B natriuretic peptide as a predictive and prognostic marker in patients with chronic heart failure.
    Rothenburger M; Wichter T; Schmid C; Stypmann J; Tjan TD; Berendes E; Etz C; Pioux A; Löher A; Wenzelburger F; Drees G; Hoffmeier A; Breithardt G; Scheld HH
    J Heart Lung Transplant; 2004 Oct; 23(10):1189-97. PubMed ID: 15477114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining the use of amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the prognosis of hospitalized heart failure patients.
    Wang Y; Zhang R; Huang Y; Zhai M; Zhou Q; An T; Huang Y; Zhao X; Tian P; Zhang Y; Zhang J
    Clin Chim Acta; 2019 Apr; 491():8-14. PubMed ID: 30594544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure.
    Fu S; Xie L; Li D; Ye P; Luo L
    Clin Interv Aging; 2015; 10():359-65. PubMed ID: 25670892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
    Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF.
    Davarzani N; Sanders-van Wijk S; Karel J; Maeder MT; Leibundgut G; Gutmann M; Pfisterer ME; Rickenbacher P; Peeters R; Brunner-la Rocca HP
    J Card Fail; 2017 May; 23(5):382-389. PubMed ID: 28232046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pro-brain natriuretic peptide plasma levels, left ventricular dimensions and ejection fraction in acute dyspnoea.
    Shaikh K; Hanif B; Siddique AA; Shaikh MY; Khan MN
    J Coll Physicians Surg Pak; 2012 Dec; 22(12):751-5. PubMed ID: 23217478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score.
    Salah K; Kok WE; Eurlings LW; Bettencourt P; Pimenta JM; Metra M; Bayes-Genis A; Verdiani V; Bettari L; Lazzarini V; Damman P; Tijssen JG; Pinto YM
    Heart; 2014 Jan; 100(2):115-25. PubMed ID: 24179162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-terminal protype-B natriuretic peptide and Doppler diastolic variables are incremental for risk stratification of patients with NYHA class I-II systolic heart failure.
    Dini FL; Fontanive P; Buralli S; Panicucci E; Andreini D; Conti U; De Tommasi SM
    Int J Cardiol; 2009 Aug; 136(2):144-50. PubMed ID: 18649955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
    Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E
    Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the plasma brain natriuretic peptide in differentiating patients with congestive heart failure from other diseases.
    Sirithunyanont C; Leowattana W; Sukumalchantra Y; Chaisupamonkollarp S; Watanawaroon S; Chivatanaporn B; Bhuripanyo K; Mahanonda N
    J Med Assoc Thai; 2003 May; 86 Suppl 1():S87-95. PubMed ID: 12866774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.
    de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A
    Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes of plasma norepinephrine and serum N-terminal pro-brain natriuretic peptide after exercise training predict survival in patients with heart failure.
    Rengo G; Pagano G; Parisi V; Femminella GD; de Lucia C; Liccardo D; Cannavo A; Zincarelli C; Komici K; Paolillo S; Fusco F; Koch WJ; Perrone Filardi P; Ferrara N; Leosco D
    Int J Cardiol; 2014 Feb; 171(3):384-9. PubMed ID: 24388546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.